RSS   Newsletter   Contact   Advertise with us

Editas Medicine appoints Andrew Hirsch to board

Staff Writer | Cambridge, Mass., USA | June 1, 2017
Editas MedicineEditas Medicine, a genome editing company, announced the appointment of Andrew Hirsch to its board of directors.
Mr. Hirsch will also serve as chairman of the audit committee of the board.

He is currently Chief Financial Officer of Agios Pharmaceuticals.

Mr. Hirsch has more than 20 years of experience in a range of strategic and operating roles in business, including more than 15 years in the biotech industry.

Prior to his current role at Agios, Mr. Hirsch served as president and chief executive officer of BIND Therapeutics.

Earlier in his career, he held various leadership roles at Avila Therapeutics and Biogen.

Mr. Hirsch holds an MBA from the Tuck School at Dartmouth College and a Bachelor of Arts in Economics from the University of Pennsylvania.


 LATEST MOVES FROM Massachusetts 


MORE INSIDE POST